LncRNA LINC01133 Targeting miR-141-5p to Mediate the Progression and Ameliorate Poor Prognosis of Prostate Cancer

Abstract

Prostate cancer is a slowly progressive cancer that develops in the epithelial cells of the prostate, which is prone to bone metastasis. In recent years, with the improvement of living conditions and the extension of life expectancy, the incidence of prostate cancer has also increased year by year in China. This study mainly focuses on the regulatory mechanism of lncRNA LINC01133 (LINC01133) in the progression of prostate cancer, providing new possibilities for the development of prognostic pathways for patients. Prostate cancer patients were diagnosed according to the magnetic resonance imaging (MRI). LINC01133 level was determined by RT-qPCR assays. The clinical significance and prognostic value of LINC01133 in prostate cancer were assessed through the chi-square analysis, Kaplan-Meier curves, and multivariate Cox regression analysis. In vitro cell experiments were performed by CCK-8 and Transwell methods. Luciferase activity assay and Pearson analysis were used to explain the relationship between LINC01133 and miR-141-5p. LINC01133 was decreased in prostate cancer tissue and cell specimens, which was associated with shorter overall survival. The abnormally high expression of LINC01133 directly targeted miR-141-5p and affected the normal growth and behavior of prostate cancer cells, while miR-141-5p mimic alleviated the inhibitory ability of LINC01133 on prostate cancer cells. LINC01133 sponge miR-141-5p mediated the progression of prostate cancer, and LINC01133 may be a potential prognostic marker for prostate cancer patients.